Use of Inflammatory Markers to Guide Cancer Treatment

Patient‐related factors, especially markers of inflammatory response, are prognostic in many common solid cancers. Here we review how such markers, in particular the acute‐phase proteins C‐reactive protein and albumin and a differential white cell count, can predict treatment outcomes in cancer pati...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2011-09, Vol.90 (3), p.475-478
Main Authors: Clarke, S J, Chua, W, Moore, M, Kao, S, Phan, V, Tan, C, Charles, K, McMillan, D C
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biomarkers - blood
C-Reactive Protein - analysis
Humans
Inflammation - physiopathology
Medical sciences
Neoplasms - blood
Neoplasms - drug therapy
Neoplasms - surgery
Neoplasms - therapy
Pharmacology. Drug treatments
Prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patient‐related factors, especially markers of inflammatory response, are prognostic in many common solid cancers. Here we review how such markers, in particular the acute‐phase proteins C‐reactive protein and albumin and a differential white cell count, can predict treatment outcomes in cancer patients. The review examines the literature pertaining to surgery, chemotherapy, and radiotherapy and discusses how inflammatory markers might be incorporated into the planning and monitoring of cancer treatments. Clinical Pharmacology & Therapeutics (2011) 90 3, 475–478. doi:10.1038/clpt.2011.122
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2011.122